Apheresis News

Apheresis was first developed by the Japanese doctor Agishi in 1956 due to the so-called Minamata catastrophe. Minamata is synonymous with environmental damage due to improper disposal of various environmental toxins, such as mercury in particular, which lead to serious damage to the health of the nervous system and the immune system. Dr. Agishi successfully released the blood and internal organs of mercury for the first time.

The filter technology has been decisively developed so that today we are able to deal with the environmental toxins that are very common in our everyday life, such as various types of micro-plastics, pesticides in food, industrial solvents, wood preservatives and other toxic heavy metals such as lead, arsenic, cadmium and aluminum targeted to remove.

A crucial further development in the early 2000s was the possibility to filter out malformed autoimmune antibodies and inflammation mediators / inflammation factors from the blood and the internal organs, which are used to develop the worldwide increasing autoimmune diseases such as rheumatism, autoimmune thyroid diseases, multiple sclerosis, chronic fatigue syndrome, multiple Chemical sensitivity and other autoimmune or inflammatory diseases. It has also been possible to wash out fat that causes disease (cholesterol, lipoprotein A etc. pp.), Which increases the risk of heart attacks and strokes. Apheresis sustainably improves the microcirculation, i.e. the blood flow in the smallest, finest end sections of the arteries, and thus ensures improved oxygen and nutrient supply to the tissue.

Around 7,500 evidence-based studies have been available since 1980 for the effectiveness of therapeutic apheresis; the study situation of double membrane filtration apheresis - as used in our INUSpheresis, as such is currently documented very well with 18307 entries in pubmed (Feb. 2015) based on evidence.